Literature DB >> 9795385

Efficient induction of protective anti-malaria immunity by recombinant adenovirus.

E G Rodrigues1, F Zavala, R S Nussenzweig, J M Wilson, M Tsuji.   

Abstract

The immunogenicity of a previously constructed replication-defective recombinant adenovirus expressing the CS protein of Plasmodium yoelii was compared with that of irradiated sporozoites. We found that immunization of BALB/c mice with a single dose of this recombinant adenovirus induced a much greater CS-specific T-cell response compared with immunization with irradiated sporozoites. More importantly, we found that this recombinant adenovirus induces similar or higher levels of protective immunity than those induced by irradiated sporozoites, eliciting an appreciable resistance to malaria infection.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9795385     DOI： 10.1016/s0264-410x(98)00181-9

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  18 in total

1.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

2.  Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.

Authors:  Jairo A Fonseca; Jessica N McCaffery; Juan Caceres; Elena Kashentseva; Balwan Singh; Igor P Dmitriev; David T Curiel; Alberto Moreno
Journal:  Vaccine       Date:  2018-04-12       Impact factor: 3.641

3.  CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay.

Authors:  Jing Zhou; Alaina Kaiser; Colin Ng; Rachel Karcher; Tim McConnell; Patrick Paczkowski; Cristina Fernandez; Min Zhang; Sean Mackay; Moriya Tsuji
Journal:  Hum Vaccin Immunother       Date:  2017-07-03       Impact factor: 3.452

4.  Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.

Authors:  C Buddy Creech; Cornelia L Dekker; Dora Ho; Shanda Phillips; Sally Mackey; Cristina Murray-Krezan; Maria Grazia Pau; Jenny Hendriks; Valerie Brown; Leonard G Dally; Isabella Versteege; Kathryn M Edwards
Journal:  Hum Vaccin Immunother       Date:  2013-08-17       Impact factor: 3.452

5.  Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice.

Authors:  Christopher Palma; Michael G Overstreet; Jean-Marc Guedon; Egbert Hoiczyk; Cameron Ward; Kasey A Karen; Fidel Zavala; Gary Ketner
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

6.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

7.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

8.  A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice.

Authors:  Shigeto Yoshida; Masanori Kawasaki; Norimitsu Hariguchi; Kuniko Hirota; Makoto Matsumoto
Journal:  Infect Immun       Date:  2009-02-17       Impact factor: 3.441

9.  Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.

Authors:  Stefan Worgall; Anja Krause; JianPing Qiu; Ju Joh; Neil R Hackett; Ronald G Crystal
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

10.  A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria.

Authors:  Frédéric Coutant; Raul Yusef Sanchez David; Tristan Félix; Aude Boulay; Laxmee Caleechurn; Philippe Souque; Catherine Thouvenot; Catherine Bourgouin; Anne-Sophie Beignon; Pierre Charneau
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.